- Home
- AACT vs PHAR Comparison
AACT vs PHAR Comparison
Compare AACT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- PHAR
- Stock Information
- Founded
- AACT 2021
- PHAR 1988
- Country
- AACT United States
- PHAR Netherlands
- Employees
- AACT N/A
- PHAR N/A
- Industry
- AACT
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- PHAR Health Care
- Exchange
- AACT Nasdaq
- PHAR Nasdaq
- Market Cap
- AACT 697.5M
- PHAR 718.1M
- IPO Year
- AACT 2023
- PHAR N/A
- Fundamental
- Price
- AACT $11.51
- PHAR $11.65
- Analyst Decision
- AACT
- PHAR Strong Buy
- Analyst Count
- AACT 0
- PHAR 3
- Target Price
- AACT N/A
- PHAR $30.00
- AVG Volume (30 Days)
- AACT 694.0K
- PHAR 3.1K
- Earning Date
- AACT 01-01-0001
- PHAR 05-08-2025
- Dividend Yield
- AACT N/A
- PHAR N/A
- EPS Growth
- AACT N/A
- PHAR N/A
- EPS
- AACT 0.36
- PHAR N/A
- Revenue
- AACT N/A
- PHAR $320,708,000.00
- Revenue This Year
- AACT N/A
- PHAR $13.31
- Revenue Next Year
- AACT N/A
- PHAR $7.68
- P/E Ratio
- AACT $31.66
- PHAR N/A
- Revenue Growth
- AACT N/A
- PHAR 24.13
- 52 Week Low
- AACT $10.64
- PHAR $6.65
- 52 Week High
- AACT $11.45
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- AACT 86.09
- PHAR 69.87
- Support Level
- AACT $11.27
- PHAR $10.02
- Resistance Level
- AACT $11.29
- PHAR $10.89
- Average True Range (ATR)
- AACT 0.04
- PHAR 0.23
- MACD
- AACT 0.02
- PHAR 0.11
- Stochastic Oscillator
- AACT 96.67
- PHAR 100.00
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.